Prescription medicine

Avacincaptad Brand names: Izervay

Avacincaptad (Izervay) is a prescription medicine with an FDA approval on record since 2023. No generic is listed in FDA's NDC Directory.

No generic listed

Check it at the source: the avacincaptad FDA label on DailyMed (effective February 27, 2026, Astellas Pharma US, Inc.); the NDA 217225 record on Drugs@FDA; every avacincaptad label on DailyMed.

Highlights of the record

FDA label of February 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage
IZERVAY ® is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Forms and strengths

20 mg/ml

Injection.

On the market

Earliest approval on file: August 4, 2023 Izervay, Astellas; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: No generic approved
Labelers listed (NDC): 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Last listed patent: July 11, 2034 Izervay injection; not a generic launch date

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded

What is avacincaptad used for?

From the label: indications and usage
IZERVAY ® is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). IZERVAY is a complement inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) ( 1 ).

FDA pharmacologic class: Complement Inhibitor.

Source: FDA drug label (IZERVAY), Astellas Pharma US, Inc., effective February 27, 2026 (SPL set 1642fe6a-dc26-4d20-ae6e-654af744e3bd), via openFDA; the full label on DailyMed

Is there a generic for avacincaptad (Izervay)?

No generic avacincaptad is approved (Drugs@FDA, October 8, 2026).

The Orange Book lists 6 patents for Izervay injection: the compound patent runs to February 14, 2027, and the last listed entry to July 11, 2034. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

2023 earliest approval on file
2034 last listed patent

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What next?

Other complement inhibitors: the pharmacologic class, with prices and generics
Check an interaction: what two or more labels say about each other